{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:54:46Z","timestamp":1790787286092,"version":"4.1.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["JASN"],"published-print":{"date-parts":[[2022,1]]},"abstract":"\n Significance Statement<\/jats:title>\n \n Hyperphosphatemia may contribute to secondary hyperparathyroidism among patients with CKD, but the mechanism responsible remains uncertain. Recent\n in vitro<\/jats:italic>\n studies indicate that high levels of phosphorus attenuate the level of calcium receptor activation, and this observation has led to speculation that hyperphosphatemia diminishes the efficacy of calcimimetic agents when used clinically. Using data from large, prospective clinical trials of the calcimimetic agents etelcalcetide and cinacalcet, the authors demonstrate that hyperphosphatemia modestly reduces the effect of these agents in lowering parathyroid hormone (PTH) levels among those with secondary hyperparathyroidism undergoing hemodialysis. These findings demonstrate a role for phosphate as a negative modulator of calcium receptor activation\n in vivo<\/jats:italic>\n in humans, but overall, it does not modify the PTH-lowering effect of either agent in a therapeutically meaningful way.\n <\/jats:p>\n <\/jats:sec>\n \n Background<\/jats:title>\n \n Phosphorus levels in the range seen clinically among patients undergoing dialysis have been reported to attenuate calcium receptor activation and modify parathyroid hormone (PTH) release from isolated parathyroid glands\n in vitro<\/jats:italic>\n . Some clinicians and providers of dialysis thus have suggested that calcimimetic agents are ineffective and should not be used to manage secondary hyperparathyroidism among those undergoing dialysis when serum phosphorus concentrations exceed certain threshold levels.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n To determine whether hyperphosphatemia diminishes the therapeutic response to calcimimetic agents, we used data from large clinical trials to analyze the effects of etelcalcetide and cinacalcet to lower plasma PTH levels in individuals on hemodialysis who had secondary hyperparathyroidism and varying degrees of hyperphosphatemia.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Plasma PTH levels declined progressively during 26 weeks of treatment with either etelcalcetide or cinacalcet without regard to the degree of hyperphosphatemia at baseline. However, with each calcimimetic agent, the decreases in PTH from baseline were less at each interval of follow-up during the trials among participants with serum phosphorus levels above one of three prespecified threshold values compared with those with serum phosphorus levels below these thresholds.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n These\n in vivo<\/jats:italic>\n findings are the first in humans to support the idea that hyperphosphatemia attenuates calcium receptor activation by calcium ions and by calcimimetic agents. The effect of hyperphosphatemia on the responsiveness to calcimimetic agents appears relatively modest, however, and unlikely to be significant therapeutically. The efficacy of treatment with calcimimetic agents for lowering plasma PTH levels among those with secondary hyperparathyroidism remains robust despite substantial elevations in serum phosphorus.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1681\/asn.2021060825","type":"journal-article","created":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T13:55:19Z","timestamp":1635947719000},"page":"201-212","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["Activation of the Calcium Receptor by Calcimimetic Agents Is Preserved Despite Modest Attenuating Effects of Hyperphosphatemia"],"prefix":"10.1681","volume":"33","author":[{"given":"William G.","family":"Goodman","sequence":"first","affiliation":[{"name":"Nephrology Therapeutic Area, Global Medical Affairs, Amgen, Inc., Thousand Oaks, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald T.","family":"Ward","sequence":"additional","affiliation":[{"name":"Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Martin","sequence":"additional","affiliation":[{"name":"St. Louis University, St. Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Drayer","sequence":"additional","affiliation":[{"name":"Nephrology Therapeutic Area, Global Medical Affairs, Amgen, Inc., Thousand Oaks, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Moore","sequence":"additional","affiliation":[{"name":"Nephrology Therapeutic Area, Global Medical Affairs, Amgen, Inc., Thousand Oaks, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahong","family":"Xu","sequence":"additional","affiliation":[{"name":"Nephrology Therapeutic Area, Global Medical Affairs, Amgen, Inc., Thousand Oaks, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Lai","sequence":"additional","affiliation":[{"name":"Nephrology Therapeutic Area, Global Medical Affairs, Amgen, Inc., Thousand Oaks, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3561-6345","authenticated-orcid":false,"given":"Yun","family":"Chon","sequence":"additional","affiliation":[{"name":"Nephrology Therapeutic Area, Global Medical Affairs, Amgen, Inc., Thousand Oaks, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward. F.","family":"Nemeth","sequence":"additional","affiliation":[{"name":"MetisMedica, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,1]]},"reference":[{"key":"B1-20240826","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/sdi.12357","article-title":"The use of calcimimetics for the treatment of secondary hyperparathyroidism: a 10 year evidence review","volume":"28","author":"Rodr\u00edguez","year":"2015","journal-title":"Semin Dial"},{"key":"B2-20240826","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1681\/ASN.V1341017","article-title":"The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism","volume":"13","author":"Goodman","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"B3-20240826","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"The calcimimetic cinacalcet hydrochloride for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"N Engl J Med"},{"key":"B4-20240826","doi-asserted-by":"crossref","first-page":"e0195316","DOI":"10.1371\/journal.pone.0195316","article-title":"A novel calcimimetic agent, evocalcet (MT-4580\/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro","volume":"13","author":"Kawata","year":"2018","journal-title":"PLoS One"},{"key":"B5-20240826","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.kint.2018.05.013","article-title":"Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism","volume":"94","author":"Fukagawa","year":"2018","journal-title":"Kidney Int"},{"key":"B6-20240826","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/jama.2016.19456","article-title":"Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: two randomized clinical trials","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"},{"key":"B7-20240826","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.pmch.2017.12.001","article-title":"Discovery and development of calcimimetic and calcilytic compounds","volume":"57","author":"Nemeth","year":"2018","journal-title":"Prog Med Chem"},{"key":"B8-20240826","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00223-015-0052-z","article-title":"Calcimimetic and calcilytic drugs: feats, flops, and futures","volume":"98","author":"Nemeth","year":"2016","journal-title":"Calcif Tissue Int"},{"key":"B9-20240826","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1681\/ASN.2004060512","article-title":"Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study","volume":"16","author":"Lindberg","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"B10-20240826","doi-asserted-by":"crossref","first-page":"c124","DOI":"10.1159\/000345164","article-title":"Relationship between reductions in parathyroid hormone and serum phosphorus during the management of secondary hyperparathyroidism with calcimimetics in hemodialysis patients","volume":"121","author":"Cooper","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"B11-20240826","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"Chertow","year":"2012","journal-title":"N Engl J Med"},{"key":"B12-20240826","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","article-title":"The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis","volume":"26","author":"Raggi","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"B13-20240826","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jama.2016.19468","article-title":"Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"},{"key":"B14-20240826","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1152\/physrev.2001.81.1.239","article-title":"Extracellular calcium sensing and extracellular calcium signaling","volume":"81","author":"Brown","year":"2001","journal-title":"Physiol Rev"},{"key":"B15-20240826","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1073\/pnas.97.9.4814","article-title":"L-amino acid sensing by the extracellular Ca2+-sensing receptor","volume":"97","author":"Conigrave","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B16-20240826","doi-asserted-by":"crossref","first-page":"5","DOI":"10.7554\/eLife.13662","article-title":"Structural mechanism of ligand activation in human calcium-sensing receptor","volume":"5","author":"Geng","year":"2016","journal-title":"eLife"},{"key":"B17-20240826","doi-asserted-by":"crossref","first-page":"21711","DOI":"10.1073\/pnas.1922231117","article-title":"Illuminating the allosteric modulation of the calcium-sensing receptor","volume":"117","author":"Liu","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B18-20240826","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/00000441-199906000-00004","article-title":"The role of phosphorus in the development of secondary hyperparathyroidism and parathyroid cell proliferation in chronic renal failure","volume":"317","author":"Slatopolsky","year":"1999","journal-title":"Am J Med Sci"},{"key":"B19-20240826","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1046\/j.1523-1755.1999.07304.x","article-title":"Pathogenesis of secondary hyperparathyroidism","volume":"73","author":"Slatopolsky","year":"1999","journal-title":"Kidney Int Suppl"},{"key":"B20-20240826","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/jbmr.5650110714","article-title":"Direct effect of phosphorus on parathyroid hormone secretion from whole parathyroid glands in vitro.","volume":"11","author":"Almaden","year":"1996","journal-title":"J Bone Miner Res"},{"key":"B21-20240826","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1172\/JCI118701","article-title":"Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro.","volume":"97","author":"Slatopolsky","year":"1996","journal-title":"J Clin Invest"},{"key":"B22-20240826","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1359\/jbmr.1999.14.11.1848","article-title":"Effect of phosphate on parathyroid hormone secretion in vivo","volume":"14","author":"Estepa","year":"1999","journal-title":"J Bone Miner Res"},{"key":"B23-20240826","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/oxfordjournals.ndt.a027665","article-title":"A direct effect in vitro of phosphate on PTH release from bovine parathyroid tissue slices but not from dispersed parathyroid cells","volume":"11","author":"Nielsen","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"B24-20240826","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/sj.ki.5002287","article-title":"Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics","volume":"74","author":"Goodman","year":"2008","journal-title":"Kidney Int"},{"key":"B25-20240826","doi-asserted-by":"crossref","first-page":"F1005","DOI":"10.1152\/ajprenal.00013.2004","article-title":"Role of the calcium-sensing receptor in parathyroid gland physiology","volume":"286","author":"Chen","year":"2004","journal-title":"Am J Physiol Renal Physiol"},{"key":"B26-20240826","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1038\/s41467-019-12399-9","article-title":"Phosphate acts directly on the calcium-sensing receptor to stimulate parathyroid hormone secretion","volume":"10","author":"Centeno","year":"2019","journal-title":"Nat Commun"},{"key":"B28-20240826","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1210\/jcem.83.4.4726","article-title":"Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent","volume":"83","author":"Collins","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"B29-20240826","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1124\/mol.115.098392","article-title":"Critical cysteine residues in both the calcium-sensing receptor and the allosteric activator AMG 416 underlie the mechanism of action","volume":"88","author":"Alexander","year":"2015","journal-title":"Mol Pharmacol"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.2021060825","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:25:45Z","timestamp":1786130745000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.2021060825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2021060825","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.741113290.793591030","asserted-by":"object"}]},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"2021-06-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}